Targeting TRPs in neurodegenerative disorders

Current Topics in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 322-334

  Takada, Yoshinori ^a   Numata, Tomohiro ^a,b   Mori, Yasuo ^a,b  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Ataxia; Bipolar disorders; Ca2+ homeostasis; Channelopathy; Epilepsy; Huntington's disease; Ischemia; Muscle atrophy; Neurodegenerative disorders; Neuronal cell death; Oxidative stress; Parkinson's disease; Stroke; TRP channels

Indexed keywords

4 AMINOBUTYRIC ACID; ANKYRIN; CAPSAICIN; HYPERICUM PERFORATUM EXTRACT; INTERLEUKIN 6; N METHYL DEXTRO ASPARTIC ACID; NERVE GROWTH FACTOR; POLYCYSTIN; REACTIVE OXYGEN METABOLITE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; VANILLOID RECEPTOR 3 ANTAGONIST; VANILLOID RECEPTOR ANTAGONIST;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATAXIA; BIPOLAR DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DEPRESSION; DIABETIC NEUROPATHY; EPILEPSY; EXCITOTOXICITY; GENE MUTATION; GITELMAN SYNDROME; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; ISCHEMIA; MENTAL DISEASE; MUSCLE ATROPHY; NERVOUS SYSTEM INFLAMMATION; NEURALGIA; NEUROPATHIC PAIN; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RETT SYNDROME; REVIEW; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY;

ANIMALS; CALCIUM; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 84876740911     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313030009     Document Type: Review

References (144)

1. Glenner, G.G.; Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun., 1984, 120(3), 885-890.
2. Forno, L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol., 1996, 55(3), 259-272.
3. Hodgson, J.G.; Agopyan, N.; Gutekunst, C.A.; Leavitt, B.R.; LePiane, F.; Singaraja, R.; Smith, D.J.; Bissada, N.; McCutcheon, K.; Nasir, J.; Jamot, L.; Li, X.J.; Stevens, M.E.; Rosemond, E.; Roder, J.C.; Phillips, A.G.; Rubin, E.M.; Hersch, S.M.; Hayden, M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 1999, 23(1), 181-192.
4. Shaw, C.E.; al-Chalabi, A.; Leigh, N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep., 2001, 1(1), 69-76.
5. Barnham, K.J.; Maters, C.L.; Bush, A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov., 2004, 3(3), 205-214.
6. Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci., 2003, 4(1), 49-60.
7. Bezprozvanny, I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med., 2009, 15(3), 89-100.
8. Mattson, M.P.; Tomaselli, K.J.; Rydel, R.E. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res., 1993, 621(1), 35-49.
9. Danzer, K.M.; Haasen, D.; Karow, A.R.; Moussaud, S.; Habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.; Kostka, M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci., 2007, 27(34), 9220-9232.
10. Panov, A.V.; Gutekunst, C.A.; Leavitt, B.R.; Hayden, M.R.; Burke, J.R.; Strittmatter, W.J.; Greenamyre, J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 2002, 5(8), 731-736.
11. Roy, J.; Minotti, S.; Dong, L.; Figlewicz, D.A.; Durham, H.D. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J. Neurosci., 1998, 18(23), 9673-9684.
12. Catterall, W.A. Structure and function of neuronal Ca2+ channels and their role in neurotransmitter release. Cell Calcium, 1998, 24(5-6), 307-323.
13. Burnashev, N. Calcium permeability of ligand-gated channels. Cell Calcium, 1998, 24(5-6), 325-332.
14. Barritt, G.J. Receptor-activated Ca2+ inflow in animal cells: a variety of pathways tailored to meet different intracellular Ca2+ signalling requirements. Biochem. J., 1999, 337(Pt 2), 153-169.
15. Putney, J.W.Jr. Capacitative calcium entry in the nervous system. Cell Calcium, 2003, 34(4-5), 339-344.
16. Minke, B.; Cook, B. TRP channel proteins and signal transduction. Physiol. Rev., 2002, 82(2), 429-472.
17. Clapham, D.E. TRP channels as cellular sensors. Nature, 2003, 426(6966), 517-524.
18. Nilius, B.; Owsianik, G.; Voets, T.; Peters, J.A. Transient receptor potential cation channels in disease. Physiol. Rev., 2007, 87(1), 165-217.
19. Montell, C.; Rubin, G.M. Molecular characterization of the Drosophila trp locus: a putative integral membrane protein required for phototransduction. Neuron, 1989, 2(4), 1313-1323.
20. Ramsey, I.S.; Delling, M.; Clapham, D.E. An introduction to TRP channels. Annu. Rev. Physiol., 2006, 68, 619-647.
21. Goel, M.; Sinkins, W.G.; Schilling, W.P. Selective association of TRPC channel subunits in rat brain synaptosomes. J. Biol. Chem., 2002, 277(50), 48303-48310.
22. Hofmann, T.; Schaefer, M.; Schultz, G.; Gudermann, T. Subunit composition of mammalian transient receptor potential channels in living cells. Proc. Natl. Acad. Sci. USA, 2002, 99(11), 7461-7466.
23. Gaudet, R. A primer on ankyrin repeat function in TRP channels and beyond. Mol. BioSyst., 2008, 4(5), 372-379.
24. Heiner, I.; Eisfeld, J.; Warnstedt, M.; Radukina, N.; Jüngling, E.; Lückhoff, A. Endogenous ADP-ribose enables calcium-regulated cation currents through TRPM2 channels in neutrophil granulocytes. Biochem. J., 2006, 398(2), 225-232.
25. Perraud, A.L.; Fleig, A.; Dunn, C.A.; Bagley, L.A.; Launay, P.; Schmitz, C.; Stokes, A.J.; Zhu, Q.; Bessman, M.J.; Penner, R.; Kinet, J.P.; Scharenberg, A.M. ADP-ribose gating of the calciumpermeable LTRPC2 channel revealed by Nudix motif homology. Nature, 2001, 411(6837), 595-599.
26. Sano, Y.; Inamura, K.; Miyake, A.; Mochizuki, S.; Yokoi, H.; Matsushime, H.; Furuichi, K. Immunocyte Ca2+ influx system mediated by LTRPC2. Science, 2001, 293(5533), 1327-1330.
27. Desai, B.N.; Krapivinsky, G.; Navarro, B.; Krapivinsky, L.; Carter, B.C.; Febvay, S.; Delling, M.; Penumaka, A.; Ramsey, I.S.; Manasian, Y.; Clapham, D.E. Cleavage of TRPM7 releases the kinase domain from the ion channel and regulates its participation in Fasinduced apoptosis. Dev. Cell, 2012, 22(6), 1149-1162.
28. Sun, M.; Goldin, E.; Stahl, S.; Falardeau, J.L.; Kennedy, J.C.; Acierno, J.S.Jr; Bove, C.; Kaneski, C.R.; Nagle, J.; Bromley, M.C.; Colman, M.; Schiffmann, R.; Slaugenhaupt, S.A. Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. Hum. Mol. Genet., 2000, 9(17), 2471-2478.
29. Numata, T.; Kiyonaka, S.; Kato, K.; Takahashi, N.; Mori, Y. In: Zhu, M. X., editor. TRP Channels. Boca Raton (FL): CRC Press., 2011, Chapter 3.
30. Nilius, B.; Owsianik, G. Transient receptor potential channelopathies. Pflugers Arch., 2010, 460(2), 437-450.
31. Raychowdhury, M.K.; González-Perrett, S.; Montalbetti, N.; Timpanaro, G.A.; Chasan, B.; Goldmann, W.H.; Stahl, S.; Cooney, A.; Goldin, E.; Cantiello, H.F. Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. Hum. Mol. Genet., 2004, 13(6), 617-627.
32. Hermosura, M.C.; Nayakanti, H.; Dorovkov, M.V.; Calderon, F.R.; Ryazanov, A.G.; Haymer, D.S.; Garruto, R.M. A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders. Proc. Natl. Acad. Sci. USA, 2005, 102(32), 11510-11515.
33. Hermosura, M.C.; Cui, A.M.; Go, R.C.; Davenport, B.; Shetler, C.M.; Heizer, J.W.; Schmitz, C.; Mocz, G.; Garruto, R.M.; Perraud, A.L. Altered functional properties of a TRPM2 variant in Guamanian ALS and PD. Proc. Natl. Acad. Sci. USA, 2008, 105(46), 18029-18034.
34. Auer-Grumbach, M.; Olschewski, A.; Papi, L.; Kremer, H.; McEntagart, M.E.; Uhrig, S.; Fischer, C.; Fröhlich, E.; Bálint, Z.; Tang, B.; Strohmaier, H.; Lochmüller, H.; Schlotter-Weigel, B.; Senderek, J.; Krebs, A.; Dick, K.J.; Petty, R.; Longman, C.; Anderson, N.E.; Padberg, G.W.; Schelhaas, H.J.; van Ravenswaaij-Arts, C.M.; Pieber, T.R.; Crosby, A.H.; Guelly, C. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat. Genet., 2010, 42(2), 160-164.
35. Deng, H.X.; Klein, C.J.; Yan, J.; Shi, Y.; Wu, Y.; Fecto, F.; Yau, H.J.; Yang, Y.; Zhai, H.; Siddique, N.; Hedley-Whyte, E.T.; Delong, R.; Martina, M.; Dyck, P.J.; Siddique, T. Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nat. Genet., 2010, 42(2), 165-169.
36. Landouré, G.; Zdebik, A.A.; Martinez, T.L.; Burnett, B.G.; Stanescu, H.C.; Inada, H.; Shi, Y.; Taye, A.A.; Kong, L.; Munns, C.H.; Choo, S.S.; Phelps, C.B.; Paudel, R.; Houlden, H.; Ludlow, C.L.; Caterina, M.J.; Gaudet, R.; Kleta, R.; Fischbeck, K.H.; Sumner, C.J. Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. Nat. Genet., 2010, 42(2), 170-174.
37. Schulz, J.B.; Lindenau, J.; Seyfried, J.; Dichgans, J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem., 2000, 267(16), 4904-4911.
38. Yakoubian, T.A.; Standaert, D.G. Targets for neuroprotection in Parkinson's disease. Biochim. Biophys. Acta, 2009, 1792(7), 676-687.
39. Garrido, C.; Galluzzi, L.; Brunet, M.; Puig, P.E.; Didelot, C.; Kroemer, G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ., 2006, 13(9), 1423-1433.
40. Roberts, R.A.; Smith, R.A.; Safe, S.; Szabo, C.; Tjalkens, R.B.; Robertson, F.M. Toxicological and pathophysiological roles of reactive oxygen and nitrogen species. Toxicology, 2010, 276(2), 85-94.
41. Lewén, A.; Matz, P.; Chan, P.H. Free radical pathways in CNS injury. J. Neurotrauma, 2000, 17(10), 871-890.
42. Andersen, J.K. Oxidative stress in neurodegeneration: cause or consequence? Nat. Med., 2004, 10 Suppl, S18-25.
43. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39(1), 44-84.
44. Parathath, S.R.; Parathath, S.; Tsirka, S.E. Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice. J. Cell Sci., 2005, 119(Pt 2), 339-349.
45. Miller, B.A. The role of TRP channels in oxidative stress-induced cell death. J. Membr. Biol., 2006, 209(1), 31-41.
46. Balzer, M.; Lintschinger, B.; Groschner, K. Evidence for a role of Trp proteins in the oxidative stress-induced membrane conductances of porcine aortic endothelial cells. Cardiovasc. Res., 1999, 42(2), 543-549.
47. Yoshida, T.; Inoue, R.; Morii, T.; Takahashi, N.; Yamamoto, S.; Hara, Y.; Tominaga, M.; Shimizu, S.; Sato, Y.; Mori, Y. Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nat. Chem. Biol., 2006, 2(11), 596-607.
48. Sawada, Y.; Hosokawa, H.; Matsumura, K.; Kobayashi, S. Activation of transient receptor potential ankyrin 1 by hydrogen peroxide. Eur. J. Neurosci., 2008, 27(5), 1131-1142.
49. Andersson, D.A.; Gentry, C.; Moss, S.; Bevan, S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J. Neurosci., 2008, 28(10), 2485-2494.
50. Bessac, B.F.; Sivula, M.; von Hehn, C.A.; Escalera, J.; Cohn, L.; Jordt, S.E. TRPA1 is a major oxidant sensor in murine airway sensory neurons. J. Clin. Invest., 2008, 118(5), 1899-1910.
51. Takahashi, N.; Mizuno, Y.; Kozai, D.; Yamamoto, S.; Kiyonaka, S.; Shibata, T.; Uchida, K.; Mori, Y. Molecular characterization of TRPA1 channel activation by cysteine-reactive inflammatory mediators. Channels (Austin), 2008, 2(4), 287-298.
52. Mattson, M.P. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med., 2003, 3(2), 65-94.
53. Madden, D.R. The structure and function of glutamate receptor ion channels. Nat. Rev. Neurosci., 2002, 3(2), 91-101.
54. Pellegrini-Giampietro, D.E.; Gorter, J.A.; Bennett, M.V.; Zukin, R.S. The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders. Trends Neurosci., 1997, 20(10), 464-470.
55. Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol., 2003, 4(7), 552-565.
56. Aarts, M.; Iihara, K.; Wei, W.L.; Xiong, Z.G.; Arundine, M.; Cerwinski, W.; MacDonald, J.F.; Tymianski, M. A key role for TRPM7 channels in anoxic neuronal death. Cell, 2003, 115(7), 863-877.
57. Wei, W.L.; Sun, H.S.; Olah, M.E.; Sun, X.; Czerwinska, E.; Czerwinski, W.; Mori, Y.; Orser, B.A.; Xiong, Z.G.; Jackson, M.F.; Tymianski, M.; MacDonald, J.F. TRPM7 channels in hippocampal neurons detect levels of extracellular divalent cations. Proc. Natl. Acad. Sci. USA, 2007, 104(41), 16323-16328.
58. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21(3), 383-421.
59. Hirsch, E.C.; Hunot, S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol., 2009, 8(4), 382-397.
60. Hanisch, U.K.; Kettenmann, H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci., 2007, 10(11), 1387-1394.
61. Streit, W.J. Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res. Rev., 2005, 48(2), 234-239.
62. Philips, T.; Robberecht, W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol., 2011, 10(3), 253-263.
63. Schilling, T.; Eder, C. Importance of the non-selective cation chan-nel TRPV1 for microglial reactive oxygen species generation. J. Neuroimmunol., 2009, 216(1-2), 118-121.
64. Konno, M.; Shirakawa, H.; Iida, S.; Sakimoto, S.; Matsutani, I.; Miyake, T.; Kageyama, K.; Nakagawa, T.; Shibasaki, K.; Kaneko, S. Stimulation of transient receptor potential vanilloid 4 channel suppresses abnormal activation of microglia induced by lipopolysaccharide. Glia, 2012, 60(5), 761-770.
65. Shirakawa, H.; Sakimoto, S.; Nakao, K.; Sugishita, A.; Konno, M.; Iida, S.; Kusano, A.; Hashimoto, E.; Nakagawa, T.; Kaneko, S. Transient receptor potential canonical 3 (TRPC3) mediates thrombin-induced astrocyte activation and upregulates its own expression in cortical astrocytes. J. Neurosci., 2010, 30(39), 13116-13129.
66. Pascale, A.; Etcheberrigaray, R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol. Res., 1999, 39(2), 81-88.
67. Hölscher, C. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol. Dis., 1998, 5(3), 129-141.
68. Varadarajan, S.; Yatin, S.; Aksenova, M.; Butterfield, D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol., 2000, 130(2-3), 184-208.
69. Eikelenboom, P.; Veerhuis, R.; Scheper, W.; Rozemuller, A.J.; van Gool, W.A.; Hoozemans, J. J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Transm., 2006, 113(11), 1685-1695.
70. Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergström, M.; Savitcheva, I.; Huang, G.; Estrada, S.; Ausén, B.; Debnath, M.L.; Barletta, J.; Price, J.C.; Sandell, J.; Lopresti, B.J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C.A.; Långström, B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol., 2004, 55(3), 306-319.
71. Bezprozvanny, I.; Mattson, M. P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci., 2008, 31(9), 454-463.
72. Smith, M.A.; Herson, P.S.; Lee, K.; Pinnock, R.D.; Ashford, M.L. Hydrogen-peroxide-induced toxicity of rat striatal neurones involves activation of a non-selective cation channel. J. Physiol., 2003, 547(Pt 2), 417-425.
73. Hill, K.; Tigue, N.J.; Kelsell, R.E.; Benham, C.D.; McNulty, S.; Schaefer, M.; Randall, A.D. Characterisation of recombinant rat TRPM2 and a TRPM2-like conductance in cultured rat striatal neurones. Neuropharmacology, 2006, 50(1), 89-97.
74. Fonfria, E.; Marshall, I.C.; Boyfield, I.; Skaper, S.D.; Hughes, J.P.; Owen, D.E.; Zhang, W.; Miller, B.A.; Benham, C.D.; McNulty, S. Amyloid beta-peptide(1-42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. J. Neurochem., 2005, 95(3), 715-723.
75. Demuro, A.; Mina, E.; Kayed, R.; Milton, S.C.; Parker, I.; Glabe, C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem., 2005, 280(17), 17294-17300.
76. Starkus, J.; Beck, A.; Fleig, A.; Penner, R. Regulation of TRPM2 by extraand intracellular calcium. J. Gen. Physiol., 2007, 130(4), 427-440.
77. Du, J.; Xie, J.; Yue, L. Intracellular calcium activates TRPM2 and its alternative spliced isoforms. Proc. Natl. Acad. Sci. USA, 2009, 106(17), 7239-7244.
78. Settembre, C.; Fraldi, A.; Jahreiss, L.; Spampanato, C.; Venturi, C.; Medina, D.; de Pablo, R.; Tacchetti, C.; Rubinsztein, D.C.; Ballabio, A. A block of autophagy in lysosomal storage disorders. Hum. Mol. Genet., 2008, 17(1), 119-129.
79. Martinez-Vicente, M.; Cuervo, A.M. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol., 2007, 6(4), 352-361.
80. Bollimuntha, S.; Selvaraj, S.; Singh, B.B. Emerging roles of canonical TRP channels in neuronal function. Adv. Exp. Med. Biol., 2011, 704, 573-593.
81. Zhou, F.W.; Matta, S.G.; Zhou, F.M. Constitutively active TRPC3 channels regulate basal ganglia output neurons. J. Neurosci., 2008, 28(2), 473-482.
82. Manji, H.K.; Lenox, R.H. The nature of bipolar disorder. J. Clin. Psychiatry, 2000, 61 Supp 13, 42-57.
83. Wasserman, M.J.; Corson, T.W.; Sibony, D.; Cooke, R.G.; Parikh, S.V.; Pennefather, P.S.; Li, P.P.; Warsh, J.J. Chronic lithium treatment attenuates intracellular calcium mobilization. Neuropsychopharmacology, 2004, 29(4), 759-769.
84. Uemura, T.; Kudoh, J.; Noda, S.; Kanba, S.; Shimizu, N. Characterization of human and mouse TRPM2 genes: identification of a novel N-terminal truncated protein specifically expressed in human striatum. Biochem. Biophys. Res. Commun., 2005, 328(4), 1232-1243.
85. Takahashi, N.; Kozai, D.; Kobayashi, R.; Ebert, M.; Mori, Y. Roles of TRPM2 in oxidative stress. Cell Calcium, 2011, 50(3), 279-287.
86. Nagamine, K.;Kudoh, J.; Minoshima, S.; Kawasaki, K.; Asakawa, S.; Ito, F.; Shimizu, N. Molecular cloning of a novel putative Ca2+ channel protein (TRPC7) highly expressed in brain. Genomics, 1998, 54(1), 124-131.
87. Xu, C.; Macciardi, F.; Li, P.P.; Yoon, I.S.; Cooke, R.G.; Hughes, B.; Parikh, S.V.; McIntyre, R.S.; Kennedy, J.L.; Warsh, J.J. Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2006, 141B(1), 36-43.
88. McQuillin, A.; Bass, N.J.; Kalsi, G.; Lawrence, J.; Puri, V.; Choudhury, K.; Detera-Wadleigh, S.D.; Curtis, D.; Gurling, H.M. Fine mapping of a susceptibility locus for bipolar and genetically related unipolar affective disorders, to a region containing the C21ORF29 and TRPM2 genes on chromosome 21q22.3. Mol. Psychiatry, 2006, 11(2), 134-142.
89. Yoon, I.S.; Li, P.P.; Siu, K.P.; Kennedy, J.L.; Macciardi, F.; Cooke, R.G.; Parikh, S.V.; Warsh, J.J. Altered TRPC7 gene expression in bipolar-I disorder. Biol. Psychiatry, 2001, 50(8), 620-626.
90. Amaral, M.D.; Pozzo-Miller, L. TRPC3 channels are necessary for brain-derived neurotrophic factor to activate a nonselective cationic current and to induce dendritic spine formation. J. Neurosci., 2007, 27(19), 5179-5189.
91. Amaral, M.D.; Chapleau, C.A.; Pozzo-Miller, L. Transient receptor potential channels as novel effectors of brain-derived neurotrophic factor signaling: potential implications for Rett syndrome. Pharmacol. Ther., 2007, 113(2), 394-409.
92. Ben-Mabrouk, F.; Tryba, A.K. Substance P modulation of TRPC3/7 channels improves respiratory rhythm regularity and ICAN-dependent pacemaker activity. Eur. J. Neurosci., 2010, 31(7), 1219-1232.
93. Fernández-Ruiz, J.; Hernández, M.; Ramos, J.A. Cannabinoiddopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther., 2010, 16(3), e72-91.
94. Moussaieff, A.; Yu, J.; Zhu, H.; Gattoni-Celli, S.; Shohami, E.; Kindy, M.S. Protective effects of incensole acetate on cerebral ischemic injury. Brain Res., 2012, 1443, 89-97.
95. Leuner, K.; Kazanski, V.; Müller, M.; Essin, K.; Henke, B.; Gollasch, M.; Harteneck, C.; Müller, W.E. Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J., 2007, 21(14), 4101-4111.
96. Griffith, T.N.; Varela-Nallar, L.; Dinamarca, M.C.; Inestrosa, N.C. Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy. Curr. Med. Chem., 2010, 17(5), 391-406.
97. Plato, C.C.; Garruto, R.M.; Galasko, D.; Craig, U.K.; Plato, M.; Gamst, A.; Torres, J.M.; Wiederholt, W. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am. J. Epidemiol., 2003, 157(2), 149-157.
98. Hara, Y.; Wakamori, M.; Ishii, M.; Maeno, E.; Nishida, M.; Yoshida, T.; Yamada, H.; Shimizu, S.; Mori, E.; Kudoh, J.; Shimizu, N.; Kurose, H.; Okada, Y.; Imoto, K.; Mori, Y. LTRPC2 Ca2+- permeable channel activated by changes in redox status confers susceptibility to cell death. Mol. Cell, 2002, 9(1), 163-173.
99. Fonfria, E.; Mattei, C.; Hill, K.; Brown, J.T.; Randall, A.; Benham, C.D.; Skaper, S.D.; Campbell, C.A.; Crook, B.; Murdock, P.R.; Wilson, J.M.; Maurio, F.P.; Owen, D.E.; Tilling, P.L.; McNulty, S. TRPM2 is elevated in the tMCAO stroke model, transcriptionally regulated, and functionally expressed in C13 microglia. J. Recept. Signal Transduct. Res., 2006, 26(3), 179-198
100. Kaneko, S.; Kawakami, S.; Hara, Y.; Wakamori, M.; Itoh, E.; Minami, T.; Takada, Y.; Kume, T.; Katsuki, H.; Mori, Y.; Akaike, A. A critical role of TRPM2 in neuronal cell death by hydrogen peroxide. J. Pharmacol. Sci., 2006, 101(1), 66-76.
101. Bai, C.X.; Kim, S.; Li, W.P.; Streets, A.J.; Ong, A.C.; Tsiokas, L. Activation of TRPP2 through mDia1-dependent voltage gating. EMBO J., 2008, 27(9), 1345-1356.
102. Hermosura, M.C.; Garruto, R.M. TRPM7 and TRPM2-Candidate susceptibility genes for Western Pacific ALS and PD? Biochim. Biophys. Acta, 2007, 1772(8), 822-835.
103. Fecto, F.; Shi, Y.; Huda, R.; Martina, M.; Siddique, T.; Deng, H.X. Mutant TRPV4-mediated toxicity is linked to increased constitutive function in axonal neuropathies. J. Biol. Chem., 2011, 286(19), 17281-17291.
104. Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem., 1992, 59(5), 1609-1623.
105. Pedersen, S.F.; Owsianik, G.; Nilius, B. TRP channels: an overview. Cell Calcium, 2005, 38(3-4), 233-252.
106. Yamamoto, S.; Shimizu, S.; Kiyonaka, S.; Takahashi, N.; Wajima, T.; Hara, Y.; Negoro, T.; Hiroi, T.; Kiuchi, Y.; Okada, T.; Kaneko, S.; Lange, I.; Fleig, A.; Penner, R.; Nishi, M.; Takeshima, H.; Mori, Y. TRPM2-mediated Ca2+influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration. Nat. Med., 2008, 14(7), 738-747.
107. Cook, N.L.; Vink, R.; Helps, S.C.; Manavis, J.; van den Heuvel, C. Transient receptor potential melastatin 2 expression is increased following experimental traumatic brain injury in rats. J. Mol. Neurosci., 2010, 42(2), 192-199.
108. Selvaraj, S.; Sun, Y.; Singh, B.B. TRPC channels and their implication in neurological diseases. CNS Neurol. Disord. Drug Targets, 2010, 9(1), 94-104.
109. Narayanan, K.L.; Irmady, K.; Subramaniam, S.; Unsicker, K.; von Bohlen und Halbach, O. Evidence that TRPC1 is involved in hippocampal glutamate-induced cell death. Neurosci. Lett., 2008, 446(2-3), 117-122.
110. Inoue, K.; Branigan, D.; Xiong, Z.G. Zinc-induced neurotoxicity mediated by transient receptor potential melastatin 7 channels. J. Biol. Chem., 2010, 285(10), 7430-7439.
111. Coombes, E.; Jiang, J.; Chu, X.P.; Inoue, K.; Seeds, J.; Branigan, D.; Simon, R.P.; Xiong, Z.G. Pathophysiologically relevant levels of hydrogen peroxide induce glutamate-independent neurodegeneration that involves activation of transient receptor potential melastatin 7 channels. Antioxid. Redox Signal., 2011, 14(10), 1815-1827.
112. Nuñez-Villena, F.; Becerra, A.; Echeverría, C.; Briceño, N.; Porras, O.; Armisén, R.; Varela, D.; Montorfano, I.; Sarmiento, D.; Simon, F. Increased expression of the transient receptor potential melastatin 7 channel is critically involved in lipopolysaccharide-induced reactive oxygen species-mediated neuronal death. Antioxid. Redox Signal., 2011, 15(9), 2425-2438.
113. Jiang, H.; Tian, S.L.; Zeng, Y.; Li, L.L.; Shi, J. TrkA pathway(s) is involved in regulation of TRPM7 expression in hippocampal neurons subjected to ischemic-reperfusion and oxygen-glucose deprivation. Brain Res. Bull., 2008, 76(1-2), 124-130.
114. Tian, S.L.; Jiang, H.; Zeng, Y.; Li, L.L.; Shi, J. NGF-induced reduction of an outward-rectifying TRPM7-like current in rat CA1 hippocampal neurons. Neurosci. Lett., 2007, 419(2), 93-98.
115. Sun, H.S.; Jackson, M.F.; Martin, L.J.; Jansen, K.; Teves, L.; Cui, H.; Kiyonaka, S.; Mori, Y.; Jones, M.; Forder, J.P.; Golde, T.E.; Orser, B.A.; MacDonald, J.F.; Tymianski, M. Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia. Nat. Neurosci., 2009, 12(10), 1300-1307.
116. Simard, J.M.; Kahle, K.T.; Gerzanich, V. Molecular mechanisms of microvascular failure in central nervous system injury--synergistic roles of NKCC1 and SUR1/TRPM4. J. Neurosurg., 2010, 113(3), 622-629.
117. Gerzanich, V.; Woo, S.K.; Vennekens, R.; Tsymbalyuk, O.; Ivanova, S.; Ivanov, A.; Geng, Z.; Chen, Z.; Nilius, B.; Flockerzi, V.; Freichel, M.; Simard, J.M. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. Nat. Med., 2009, 15(2), 185-191.
118. Moussaieff, A.; Yu, J.; Zhu, H.; Gattoni-Celli, S.; Shohami, E.; Kindy, M.S. Protective effects of incensole acetate on cerebral ischemic injury. Brain Res., 2012, 1443, 89-97.
119. Butenko, O.; Dzamba, D.; Benesova, J.; Honsa, P.; Benfenati, V.; Rusnakova, V.; Ferroni, S.; Anderova, M. The increased activity of TRPV4 channel in the astrocytes of the adult rat hippocampus after cerebral hypoxia/ischemia. PLoS One, 2012, 7(6), e39959.
120. Wang, M.; Bianchi, R.; Chuang, S.C.; Zhao, W.; Wong, R.K. Group I metabotropic glutamate receptor-dependent TRPC channel trafficking in hippocampal neurons. J. Neurochem., 2007, 101(2), 411-421.
121. Tai, C.; Hines, D.J.; Choi, H.B.; MacVicar, B.A. Plasma membrane insertion of TRPC5 channels contributes to the cholinergic plateau potential in hippocampal CA1 pyramidal neurons. Hippocampus, 2011, 21(9), 958-967.
122. Phelan, K.D.; Mock, M.M.; Kretz, O.; Shwe, U.T.; Kozhemyakin, M.; Greenfield, L.J.; Dietrich, A.; Birnbaumer, L.; Freichel, M.; Flockerzi, V.; Zheng, F. Heteromeric canonical transient receptor potential 1 and 4 channels play a critical role in epileptiform burst firing and seizure-induced neurodegeneration. Mol. Pharmacol., 2012, 81(3), 384-392.
123. Hartmann, J.; Dragicevic, E.; Adelsberger, H.; Henning, H.A.; Sumser, M.; Abramowitz, J.; Blum, R.; Dietrich, A.; Freichel, M.; Flockerzi, V.; Birnbaumer, L.; Konnerth, A. TRPC3 channels are required for synaptic transmission and motor coordination. Neuron, 2008, 59(3), 392-398.
124. Becker, E.B.; Oliver, P.L.; Glitsch, M.D.; Banks, G.T.; Achilli, F.; Hardy, A.; Nolan, P.M.; Fisher, E.M.; Davies, K.E. A point mutation in TRPC3 causes abnormal Purkinje cell development and cerebellar ataxia in moonwalker mice. Proc. Natl. Acad. Sci. USA, 2009, 106(16), 6706-6711.
125. Trebak, M. The puzzling role of TRPC3 channels in motor coordination. Pflugers Arch., 2010, 459(3), 369-375.
126. Fu, M.; Xie, Z.; Zuo, H. TRPV1: a potential target for antiepileptogenesis. Med. Hypotheses, 2009, 73(1), 100-102.
127. Gibson, H.E.; Edwards, J.G.; Page, R.S.; Van Hook, M.J.; Kauer, J.A. TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron, 2008, 57(5), 746-759.
128. Koike, C.; Numata, T.; Ueda, H.; Mori, Y.; Furukawa, T. TRPM1: a vertebrate TRP channel responsible for retinal ON bipolar function. Cell Calcium, 2010, 48(2-3), 95-101.
129. Lepichon, J.B.; Bittel, D.C.; Graf, W.D.; Yu, S. A 15q13.3 homozygous microdeletion associated with a severe neurodevelopmental disorder suggests putative functions of the TRPM1, CHRNA7, and other homozygously deleted genes. Am. J. Med. Genet. A., 2010, 152A(5), 1300-1304.
130. Katano, M.; Numata, T.; Aguan, K.; Hara, Y.; Kiyonaka, S.; Yamamoto, S.; Miki, T.; Sawamura, S.; Suzuki, T.; Yamakawa, K.; Mori, Y. The juvenile myoclonic epilepsy-related protein EFHC1 interacts with the redox-sensitive TRPM2 channel linked to cell death. Cell Calcium, 2012, 51(2), 179-185.
131. Chen, X.; Numata, T.; Li, M.; Mori, Y.; Orser, B.A.; Jackson, M.F.; Xiong, Z.G.; MacDonald, J.F. The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations. Mol. Brain, 2010, 3, 38.
132. Walder, R.Y.; Landau, D.; Meyer, P.; Shalev, H.; Tsolia, M.; Borochowitz, Z.; Boettger, M.B.; Beck, G.E.; Englehardt, R.K.; Carmi, R.; Sheffield, V.C. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat. Genet., 2002, 31(2), 171-174.
133. Schlingmann, K.P.; Weber, S.; Peters, M.; Niemann Nejsum, L.; Vitzthum, H.; Klingel, K.; Kratz, M.; Haddad, E.; Ristoff, E.; Dinour, D.; Syrrou, M.; Nielsen, S.; Sassen, M.; Waldegger, S.; Seyberth, H.W.; Konrad, M. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat. Genet., 2002, 31(2), 166-170.
134. Schlingmann, K.P.; Sassen, M.C.; Weber, S.; Pechmann, U.; Kusch, K.; Pelken, L.; Lotan, D.; Syrrou, M.; Prebble, J.J.; Cole, D.E.; Metzger, D.L.; Rahman, S.; Tajima, T.; Shu, S.G.; Waldegger, S.; Seyberth, H.W.; Konrad, M. Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. J. Am. Soc. Nephrol., 2005, 16(10), 3061-3069.
135. Voets, T.; Nilius, B.; Hoefs, S.; van der Kemp, A.W.; Droogmans, G.; Bindels, R.J.; Hoenderop, J.G. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J. Biol. Chem., 2004, 279(1), 19-25.
136. Cao, G.; Thébault, S.; van der Wijst, J.; van der Kemp, A.; Lasonder, E.; Bindels, R.J.; Hoenderop, J.G. RACK1 inhibits TRPM6 activity via phosphorylation of the fused alpha-kinase domain. Curr. Biol., 2008, 18(3), 168-176.
137. Nijenhuis, T.; Vallon, V.; van der Kemp, A.W.; Loffing, J.; Hoenderop, J.G.; Bindels, R.J. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazideinduced hypocalciuria and hypomagnesemia. J. Clin. Invest., 2005, 115(6), 1651-1658.
138. Bach, G. Mucolipin 1: endocytosis and cation channel--a review. Pflugers Arch., 2005, 451(1), 313-317.
139. Bach, G. Mucolipidosis type IV. Mol. Genet. Metab., 2001, 73(3), 197-203.
140. Wakabayashi, K.; Gustafson, A.M.; Sidransky, E.; Goldin, E. Mucolipidosis type IV: an update. Mol. Genet. Metab., 2011, 104(3), 206-213.
141. Moran, M.M.; McAlexander, M.A.; Bíró, T.; Szallasi, A. Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug Discov., 2011, 10(8), 601-620.
142. Linde, K.; Ramirez, G.; Mulrow, C.D.; Pauls, A.; Weidenhammer, W.; Melchart, D. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. BMJ, 1996, 313(7052), 253-258
143. Weber, W.; Vander Stoep, A.; McCarty, R.L.; Weiss, N.S.; Biederman, J.; McClellan, J. Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA, 2008, 299(22), 2633-2641.
144. Chen, H.C.; Xie, J.; Zhang, Z.; Su, L.T.; Yue, L.; Runnels, L.W. Blockade of TRPM7 channel activity and cell death by inhibitors of 5-lipoxygenase. PLoS One, 2010, 5(6), e11161.